

**IN THE SPECIFICATION:**

Please enter Figures 1, 2a, 2b, 3a, 3b, and 4 submitted with the amendment of April 22, 2002.

**Support for entry of the Figures:**

The experimental results graphically represented in Figure 1 are described on pages 47-48; the experimental results graphically represented in Figure 2a are described on page 49; the experimental results graphically represented in Figure 2b are described on pages 49-50; the experimental results graphically represented in Figures 3a and 3b are described on pages 53-54; and the experimental results graphically represented in Figure 4 are described on page 55. The Applicants respectfully submit that the figures do not constitute new matter.

Please amend the claims as set forth below:

**IN THE CLAIMS:**

Claims 61-64, 70, and 73-79 are canceled; claims 60, 65-69, 71, 72, and 82-85 are amended; and new claims 86-99 are added; and claims 80 and 81 remain unchanged, as shown below. Claims 60, 65-69, 71, 72, and 81-99 are pending in the application.

- 60. (Amended) A method for treating a B cell leukemia comprising administering a therapeutically effective amount of:
- (i) an anti-CD20 antibody having B-cell depleting activity, or a fragment thereof having B-cell depleting activity; and
  - (ii) an anti-CD40L antibody that antagonizes interaction of CD40 and CD40L, or a fragment thereof that antagonizes interaction of CD40 and CD40L.
65. (Amended) The method of claim 60 wherein said B cell leukemia is selected from the group consisting of chronic B cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Burkitt's type leukemia.
66. (Amended) The method of claim 60 wherein said anti-CD20 antibody is a humanized, primatized, or chimeric anti-CD20 antibody.